Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Research suggests that COVID-19 can have a more serious effect on people with underlying long-term conditions. So far, research suggests that people with asthma are having less severe outcomes from COVID-19 than expected, despite this group of people often experiencing a more severe version of seasonal flu and other viruses.
What did the study look at?
This study aimed to understand this risk of COVID-19 in people with asthma. Researchers analysed health records of over 71,000 people with asthma in Spain. They looked at the records between January and May 2020 and assessed whether people developed COVID-19, what medication they were taking, what underlying conditions they had and whether they were hospitalised.
What do the results show?
1,006 people (1.4% of the total study population) developed COVID-19 during the study period. The people who developed COVID-19 were more likely to be older, female, smoke more often and were more likely to be living with another condition such as diabetes or obesity.
Conditions such as eczema were less common in people with asthma who developed COVID-19.
The use of inhaled corticosteroids was lower in people who needed hospital treatment due to COVID-19 compared to those who were not hospitalised.
Why is this important?
Overall, this study found that the increased risk of hospitalisation from having both asthma and COVID-19 is mainly linked with age and living with other conditions. The findings suggest that asthma medication is safe and should continue to be taken. The results also suggest that inhaled corticosteroids may be associated with a protective affect against severe COVID-19 infection.
Title: The Impact of COVID-19 on Patients with Asthma
https://erj.ersjournals.com/content/early/2020/12/10/13993003.03142-2020
Sign up to get the latest information and research on lung conditions, hear about our upcoming events and campaigns, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79